MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 16 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundaboutunlabeled
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
Neelima Denduluri, Mark R. Somerfield, Andrea Eisen, Jamie N. Holloway, Arti Hurria, Tari A. King +5 more
2016· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
129
citations
affunlabeled
Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.
Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos +14 more
2022· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
125
citations
afffundunlabeled
Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
Lillian L. Siu, Jeremy Shapiro, Derek J. Jonker, Christos S. Karapetis, John Zalcberg, John Simes +15 more
2013· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
125
citations
affunlabeled
Cancer Survivorship: Why Labels Matter
Kirsten Bell, Svetlana Ristovski‐Slijepcevic
2012· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
124
citations
fundno affunlabeled
Risk-Directed Treatment Intensification Significantly Reduces the Risk of Relapse Among Children and Adolescents With Acute Lymphoblastic Leukemia and Intrachromosomal Amplification of Chromosome 21: A Comparison of the MRC ALL97/99 and UKALL2003 Trials
Anthony V. Moorman, Hazel M. Robinson, Claire Schwab, Sue Richards, Jeremy Hancock, Christopher Mitchell +3 more
2013· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
123
citations
affaboutunlabeled
Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group
Scott A. Laurie, Isabelle Gauthier, Andrew Arnold, Frances A. Shepherd, Eric X. Chen, Glenwood D. Goss +6 more
2008· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
120
citations
aboutno affunlabeled
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
Frances A. Shepherd, J. Pereira, Tudor–Eliade Ciuleanu, E. H. Tan, V. Hirsh, S. Thongprasert +4 more
2004· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
119
citations

How this was built: Screen · Findings · About